ABEONA THERAPEUTICS INC. (ABEO) Stock Research

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.

Latest price: 5.16 · Sector: Healthcare

Recent Insider Transactions

InsiderTypeDateValue
Seshadri Vishwassell2026-09-29101091
Vazzano Joseph Waltersell2026-09-2947385.12
Vasanthavada Madhavsell2026-09-2925272.75
O'Malley Brendan M.sell2026-09-2934681.72
Alvino Marksell2026-09-0187966
Vazzano Joseph Waltersell2026-07-219651.34
Vazzano Joseph Waltersell2026-07-09173256.86
Seshadri Vishwassell2026-07-09473329.65
Vasanthavada Madhavsell2026-07-0987784.4
O'Malley Brendan M.sell2026-07-0983912.59

All insider transactions · Institutional holdings